# US 2023/0056846 A1 · Methods and compositions for cancer immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056846 A1
- Document ID: US20230056846A1
- Status: Published application
- Kind: A1
- Application number: 17/792,557
- Filed: 2021-01-13
- Published: 2023-02-23
- Earliest claimed: 2020-01-13
- Assignees: Memorial Sloan Kettering Cancer Center
- Applicants: Memorial Sloan Kettering Cancer Center
- Inventors: Luis Alberto Diaz; Benoit Rousseau; Neil H. Segal
- Web page: https://patentgrep.com/patent/US20230056846A1

## CPC

- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/655: Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

In some embodiments the present invention provides methods useful for the treatment of MMR-proficient and/or microsatellite stable (MSS) cancers and also useful for enhancing the immunogenicity of MMR-proficient and/or microsatellite stable (MSS) cancer cells, enhancing the sensitivity of MMR-proficient and/or microsatellite stable (MSS) cancer cells to immune checkpoint blockade, inducing an MMR-deficient mutational signature in MMR-proficient and/or microsatellite stable (MSS) cancer cells, and/or increasing the frequency of both missense and InDel mutations in MMR-proficient and/or microsatellite stable (MSS) cancer cells. In some embodiments such methods involve administration of a combination of temozolomide and cisplatin, or a combination of temozolomide, cisplatin and an immune checkpoint inhibitor, to a subject in need thereof.

## Claims

### Claim 1

A method of treating an MMR-proficient and/or microsatellite-stable colorectal cancer in a subject in need thereof, the method comprising: administering to a subject with an MMR-proficient and/or microsatellite-stable colorectal cancer an effective amount of: (a) temozolomide, (b) cisplatin, and (c) nivolumab, thereby treating the MMR-proficient and/or microsatellite stable colorectal cancer in the subject.

### Claim 2 (depends on 1)

The method of claim 1, further comprising performing a test to determine if the subject has a MMR-proficient and/or microsatellite-stable colorectal cancer prior to admninistering the temozolomide, cisplatin and nivolumab.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancer is immune checkpoint inhibitor resistant.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cancer was previously treated with, and exhibited resistance to, one or more immune checkpoint inhibitors.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer is nivolumab resistant.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cancer was previously treated with, and exhibited resistance to, nivolumab.

### Claim 7 (depends on 1)

The method of claim 1, wherein the nivolumab is administered by IV infusion.

### Claim 8 (depends on 1)

The method of claim 1, wherein the temozolomide is administered orally.

### Claim 9 (depends on 1)

The method of claim 1, wherein the temozolomide is administered by IV infusion.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cisplatin is administered by IV infusion.

### Claim 11 (depends on 1)

The method of claim 1, wherein the nivolumab is administered to the subject by IV infusion about at about 480 mg about every 4 weeks (480 mg Q4W).

### Claim 12 (depends on 1)

The method of claim 1, wherein the temozolomoide is administered to the subject orally at about 50-200 mg/m2, day 1-5, about every 4 weeks (Q4W).

### Claim 13 (depends on 1)

The method of claim 1, wherein the cisplatin is administered to the subject by IV infusion at about 40 mg/m2 about every 2 weeks (40 mg/m2 Q2W).

### Claim 14

A method of treating an MMR-proficient and/or microsatellite-stable cancer in a subject in need thereof, the method comprising: administering to a subject with MMR-proficient and/or microsatellite-stable cancer an effective amount of: (a) an imidazotetrazine chemotherapeutic agent, and (b) a platinum-containing chemotherapeutic agent, thereby treating the MMR-proficient and/or microsatellite stable cancer in the subject.

### Claim 15 (depends on 14)

The method of claim 14, further comprising administering to the subject an effective amount of an immune checkpoint inhibitor.

### Claim 16 (depends on 14, 15)

The method of claim 14 or claim 15, further comprising performing a test to determine if the subject has a MMR-proficient and/or microsatellite-stable cancer prior to administering the imidazotetrazine chemotherapeutic agent, platinum-containing chemotherapeutic agent and/or immune checkpoint inhibitor to the subject.

### Claim 17 (depends on 14, 15, 16)

The method of any of claims 14-16, wherein the cancer is colorectal cancer, pancreatic cancer, or melanoma.

### Claim 18 (depends on 14, 15, 16)

The method of any of claims 14-16, wherein the cancer is colorectal cancer.

### Claim 19 (depends on 14, 15, 16, 17, 18)

The method of claims 14-18, wherein the cancer is immune checkpoint inhibitor resistant.

### Claim 20 (depends on 14, 15, 16, 17, 18)

The method of any of claims 14-18, wherein the cancer was previously treated with, and exhibited resistance to, one or more immune checkpoint inhibitors.

### Claim 21 (depends on 14, 15, 16, 17, 18, 19, 20)

The method of any of claims 14-20, wherein the imidazotetrazine chemotherapeutic agent is selected from the group consisting of TMZ and dacarbazine.

### Claim 22 (depends on 14, 15, 16, 17, 18, 19, 20)

The method of any of claims 14-20, wherein the imidazotetrazine chemotherapeutic agent is TMZ.

### Claim 23 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any of claims 14-22, wherein the platinum-containing chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin and oxaliplatin.

### Claim 24 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any of claims 14-22, wherein the platinum-containing chemotherapeutic agent is cisplatin.

### Claim 25 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any of claims 15-24, wherein the immune checkpoint inhibitor is a PD-1, PD-L1, PD-L2 or CTLA-4 inhibitor.

### Claim 26 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any of claims 15-24, where the immune checkpoint inhibitor is selected from the group consisting of: nivolumab, pembrolizumab, tremelimumab, ipilimumab. cemiplimab, MPDL3280A, AMP-224, AMP-514 and PDR001, atezolizumab, Avelumab, Durvalumab, BMS-936559, CK-301 , tislelizumab, toripalimab, envafolimab, HLX10, and HLX20.

### Claim 27 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any of claims 15-24, where the immune checkpoint inhibitor is nivolumab.

### Claim 28 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any of any of claims 15-27, wherein the immune checkpoint inhibitor is is administered by IV infusion.

### Claim 29 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any of claims 14-27, wherein the temozolomeide is administered orally.

### Claim 30 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any of claims 14-27wherein the temozolomeide is administered by IV infusion.

### Claim 31 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any claims 14-27, wherein platinum-containing chemotherapeutic agent is administered by IV infusion.

### Claim 32 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any of claims 15-27, wherein the immune checkpoint inhibitor is nivolumab, and wherein the nivolumab is administered to the subject by IV infusion about at about 480 mg about every 4 weeks (480 mg Q4W).

### Claim 33 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any of claims 14-27, wherein the temozolomoide is administered to the subject orally or by IV infusion at about 50-200 mg/m2, day 1-5, about every 4 weeks (Q4W).

### Claim 34 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any of claims 14-27, wherein the temozolomoide is administered to the subject by IV infusion at about 75 mg/m2 daily.

### Claim 35 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any of claims 14-27, wherein the platinum-containing chemotherapeutic agent is cisplatin, and wherein the cisplatin is administered to the subject by IV infusion at about 30 mg/m2 weekly, or at about 40 mg/m2 about every 2 weeks (40 mg/m2 Q2W), or at about 60 to 100 mg/m2 every 3 to 4 weeks.

### Claim 36 (depends on 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any of claims 14-27, wherein the platinum-containing chemotherapeutic agent is cisplatin, and wherein the cisplatin is administered to the subject by IV infusion at about 75 mg/m2 daily.

### Claim 37

The method of any of the preceding claims wherein the method enhances the immunogenicity of MMR-proficient and/or microsatellite stable (MSS) cancer cells in the subject.

### Claim 38

The method of any of the preceding claims wherein the method enhances the sensitivity of MMR-proficient and/or microsatellite stable (MSS) cancer cells in the subject to immune checkpoint blockade.

### Claim 39

The method of any of the preceding claims wherein the method induces an MMR-deficient mutational signature in MMR-proficient and/or microsatellite stable (MSS) cancer cells in the subject.

### Claim 40

The method of any of the preceding claims wherein the method increases the frequency of both missense and InDel mutations in MMR-proficient and/or microsatellite stable (MSS) cancer cells in the subject.

### Claim 41

A method of enhancing the immunogenicity of MMR-proficient and/or microsatellite stable (MSS) cancer cells, the method comprising contacting the cancer cells with an effective amount of an imidazotetrazine chemotherapeutic agent and a platinum-containing chemotherapeutic agent.

### Claim 42 (depends on 41)

The method of claim 41, wherein the imidazotetrazine chemotherapeutic agent is selected from the group consisting of TMZ and dacarbazine.

### Claim 43 (depends on 41)

The method of claim 41, wherein the imidazotetrazine chemotherapeutic agent is TMZ.

### Claim 44 (depends on 41, 42, 43)

The method of any of claims 41-43, wherein the platinum-containing chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin and oxaliplatin.

### Claim 45 (depends on 41, 42, 43)

The method of any of claims 41-43, wherein the platinum-containing chemotherapeutic agent is cisplatin.

### Claim 46 (depends on 41, 42, 43, 44, 45)

The method of any of claims 41-45, wherein the cancer cells are colorectal cancer cells.

### Claim 47 (depends on 41, 42, 43, 44, 45)

The method any of claims 41-45, wherein the cancer cells are pancreatic cancer cells.

### Claim 48 (depends on 41, 42, 43, 44, 45)

The method of any of claims 41-45, wherein the cancer cells are melanoma cells.

### Claim 49 (depends on 41, 42, 43, 44, 45, 46, 47, 48)

The method of any of claims 41-48 wherein the cancer cells are in a subject and wherein the method comprises administering the temozolomide and the platinum-containing chemotherapeutic agent to the subject.

### Claim 50

A method of enhancing the sensitivity of MMR-proficient and/or microsatellite stable (MSS) cancer cells to immune checkpoint blockade, the method comprising contacting the cancer cells with an effective amount of an imidazotetrazine chemotherapeutic agent and a platinum-containing chemotherapeutic agent.

### Claim 51 (depends on 50)

The method of claim 50, wherein the imidazotetrazine chemotherapeutic agent is selected from the group consisting of TMZ and dacarbazine.

### Claim 52 (depends on 50)

The method of claim 50, wherein the imidazotetrazine chemotherapeutic agent is TMZ.

### Claim 53 (depends on 50, 51, 52)

The method of any of claims 50-52, wherein the platinum-containing chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin and oxaliplatin.

### Claim 54 (depends on 50, 51, 52)

The method of any of claims 50-52, wherein the platinum-containing chemotherapeutic agent is cisplatin.

### Claim 55 (depends on 50, 51, 52, 53, 54)

The method of any of claims 50-54, wherein the cancer cells are colorectal cancer cells.

### Claim 56 (depends on 50, 51, 52, 53, 54)

The method of any of claims 50-54, wherein the cancer cells are pancreatic cancer cells.

### Claim 57 (depends on 50, 51, 52, 53, 54)

The method of any of claims 50-54, wherein the cancer cells are melanoma cells.

### Claim 58 (depends on 50, 51, 52, 53, 54, 55, 56, 57)

The method of any of claims 50-57, wherein the cancer cells are in a subject and wherein the method comprises administering the temozolomide and the platinum-containing chemotherapeutic agent to the subject.

### Claim 59

A method of inducing an MMR-deficient mutational signature in MMR-proficient and/or microsatellite stable (MSS) cancer cells, the method comprising contacting the cancer cells with an effective amount of temozolomide and a platinum-containing chemotherapeutic agent.

### Claim 60 (depends on 59)

The method of claim 59, wherein the imidazotetrazine chemotherapeutic agent is selected from the group consisting of TMZ and dacarbazine.

### Claim 61 (depends on 59)

The method of claim 59, wherein the imidazotetrazine chemotherapeutic agent is TMZ.

### Claim 62 (depends on 59, 60, 61)

The method of any of claims 59-61, wherein the platinum-containing chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin and oxaliplatin.

### Claim 63 (depends on 59, 60, 61)

The method of any of claims 59-61, wherein the platinum-containing chemotherapeutic agent is cisplatin.

### Claim 64 (depends on 59, 60, 61, 62, 63)

The method of any of claims 59-63, wherein the cancer cells are colorectal cancer cells.

### Claim 65 (depends on 59, 60, 61, 62, 63)

The method of any of claims 59-63, wherein the cancer cells are pancreatic cancer cells.

### Claim 66 (depends on 59, 60, 61, 62, 63)

The method of any of claims 59-63, wherein the cancer cells are melanoma cells.

### Claim 67 (depends on 59, 60, 61, 62, 63, 64, 65, 66)

The method of any of claims 59-66, wherein the cancer cells are in a subject and wherein the method comprises administering the temozolomide and the platinum-containing chemotherapeutic agent to the subject.

### Claim 68

A method of increasing the frequency of both missense and InDel mutations in MMR-proficient and/or microsatellite stable (MSS) cancer cells, the method comprising contacting the cancer cells with an effective amount of an imidazotetrazine chemotherapeutic agent and a platinum-containing chemotherapeutic agent.

### Claim 69 (depends on 68)

The method of claim 68, wherein the imidazotetrazine chemotherapeutic agent is selected from the group consisting of TMZ and dacarbazine.

### Claim 70 (depends on 68)

The method of claim 68, wherein the imidazotetrazine chemotherapeutic agent is TMZ.

### Claim 71 (depends on 68, 69, 70)

The method of any of claims 68-70, wherein the platinum-containing chemotherapeutic agent is selected from the group consisting of cisplatin, carboplatin and oxaliplatin.

### Claim 72 (depends on 68, 69, 70)

The method of any of claims 68-70, wherein the platinum-containing chemotherapeutic agent is cisplatin.

### Claim 73 (depends on 68, 69, 70, 71, 72)

The method of any of claims 68-72, wherein the cancer cells are colorectal cancer cells.

### Claim 74 (depends on 68, 69, 70, 71, 72)

The method of any of claims 68-72, wherein the cancer cells are pancreatic cancer cells.

### Claim 75 (depends on 68, 69, 70, 71, 72)

The method of any of claims 68-72, wherein the cancer cells are melanoma cells.

### Claim 76 (depends on 68, 69, 70, 71, 72, 73, 74, 75)

The method of any of claims 68-75, wherein the cancer cells are in a subject and wherein the method comprises administering the imidazotetrazine chemotherapeutic agent and the platinum-containing chemotherapeutic agent to the subject.

### Claim 77

A pharmaceutical composition comprising: (a) an imidazotetrazine chemotherapeutic agent and (b) a platinum-containing chemotherapeutic agent.

### Claim 78

A pharmaceutical composition comprising: (a) TMZ and (b) cisplatin.

### Claim 79

A pharmaceutical composition comprising: (a) a platinum-containing chemotherapeutic agent, and (b) an immune checkpoint inhibitor.

### Claim 80

A pharmaceutical composition comprising: (a) cisplatin, and (b) nivolumab.

### Claim 81

A pharmaceutical composition comprising: (a) an imidazotetrazine chemotherapeutic agent, (b) a platinum-containing chemotherapeutic agent, and (c) an immune checkpoint inhibitor.

### Claim 82

A pharmaceutical composition comprising: (a) temozolomide, (b) cisplatin, and (c) nivolumab.

### Claim 83 (depends on 77, 78, 79, 80, 81, 82)

A pharmaceutical composition according to claim 77-82, for use in treatment of a MMR-proficient and/or microsatellite stable cancer in a subject in need thereof.

### Claim 84 (depends on 77, 78, 79, 80, 81, 82)

A pharmaceutical composition according to claim 77-82, for use in treatment of a MMR-proficient and/or microsatellite stable colorectal cancer in a subject in need thereof.

### Claim 85 (depends on 77, 78, 79, 80, 81, 82)

A pharmaceutical composition according to claim 77-82, for use in treatment of a MMR-proficient and/or microsatellite stable pancreatic cancer in a subject in need thereof.

### Claim 86 (depends on 77, 78, 79, 80, 81, 82)

A pharmaceutical composition according to claim 77-82, for use in treatment of a MMR-proficient and/or microsatellite stable melanoma in a subject in need thereof.

### Claim 87

A combination comprising: (a) an imidazotetrazine chemotherapeutic agent and (b) a platinum-containing chemotherapeutic agent, for use in treatment of a MMR-proficient and/or microsatellite stablecancer in a subject in need thereof.

### Claim 88

A combination comprising: (a) TMZ and (b) cisplatin, for use in treatment of a MMR-proficient and/or microsatellite stablecancer in a subject in need thereof.

### Claim 89

A combination comprising: (a) a platinum-containing chemotherapeutic agent, and (b) an immune checkpoint inhibitor, for use in treatment of a MMR-proficient and/or microsatellite stablecancer in a subject in need thereof.

### Claim 90

A combination comprising: (a) cisplatin, and (b) nivolumab, for use in treatment of a MMR-proficient and/or microsatellite stablecancer in a subject in need thereof.

### Claim 91

A combination comprising: (a) an imidazotetrazine chemotherapeutic agent, (b) a platinum-containing chemotherapeutic agent, and (c) an immune checkpoint inhibitor, for use in treatment of a MMR-proficient and/or microsatellite stablecancer in a subject in need thereof.

### Claim 92

A combination comprising: (a) temozolomide, (b) cisplatin, and (c) nivolumab, for use in treatment of a MMR-proficient and/or microsatellite stablecancer in a subject in need thereof.

### Claim 93 (depends on 87, 88, 89, 90, 91, 92)

The combination for use of any of claims 87-92, wherein the MMR-proficient and/or microsatellite stable cancer is a colorectal cancer.

### Claim 94 (depends on 87, 88, 89, 90, 91, 92)

The combination for use of any of claims 87-92, wherein the MMR-proficient and/or microsatellite stable cancer is a pancreatic cancer.

### Claim 95 (depends on 87, 88, 89, 90, 91, 92)

The combination for use of any of claims 87-92, wherein the MMR-proficient and/or microsatellite stable cancer is a melanoma.
